

1 **The Effect of Dietary Oxalate on the Gut Microbiota of the Mammalian**
2 **Herbivore *Neotoma albigula***

3

4 Aaron W. Miller^{#a}, Kelly F. Oakeson^a, Colin Dale^a, M. Denise Dearing^a

5 Department of Biology, University of Utah, 257 South 1400 East, Salt Lake City,

6 Utah, USA^a

7

8 #Corresponding author: Miller, A.W. (aaron.w.miller@utah.edu)

9

10 Phone: 1 801 585 1324

11 Fax: 1 801 585 4668

12

13 Conflicts of interest: The authors declare no conflict of interest

14 Running head: Gut Microbiota Response to Dietary Oxalate

15

16 **Abstract**

17 Diet is one of the primary drivers that sculpts the form and function of the
18 mammalian gut microbiota. However, the enormous taxonomic and metabolic
19 diversity held within the gut microbiota makes it difficult to isolate specific diet-
20 microbe interactions. The objective of the current study was to elucidate
21 interactions between the gut microbiota of the mammalian herbivore, *Neotoma*
22 *albigula*, and dietary oxalate, a plant secondary compound (PSC) degraded
23 exclusively by the gut microbiota. We quantified oxalate degradation in *N.*
24 *albigula* fed increasing amounts of oxalate over time and tracked the response of
25 the fecal microbiota using high-throughput sequencing. The amount of oxalate
26 degraded *in vivo* was linearly correlated with oxalate consumed. The addition of
27 dietary oxalate was found to impact microbial species diversity by increasing the
28 representation of certain taxa, some of which are known to be capable of
29 degrading oxalate (e.g., *Oxalobacter* spp.). Furthermore, the relative abundance
30 of 117 OTUs exhibited a significant correlation with oxalate consumption. The
31 results of this study indicate that dietary oxalate induces complex interactions
32 within the gut microbiota that includes an increase in relative abundance of a
33 community of bacteria that may contribute either directly or indirectly to oxalate
34 degradation in mammalian herbivores.

35 Key words: oxalate-degrading bacteria; gut microbiota; plant secondary
36 compounds; oxalate; biotransformation

37

38 **Introduction**

39 Mammals live in a complex and largely symbiotic relationship with a gut
40 microbiota. This microbiota harbors 150 times more genes than the host and
41 exhibits complex interactions with the host's diet (1-3). In mammalian herbivores,
42 diverse intestinal bacteria ferment a diet high in recalcitrant cellulose and in turn
43 synthesize nutrients from the diet in a form more amenable to absorption by the
44 host (4). Furthermore, mammalian herbivores harbor greater microbial diversity
45 in their gut than either omnivores or carnivores (1). Despite the progress of
46 research into the interactions between the mammalian gut microbiota and diet,
47 the isolation of specific diet-microbe interactions in such a complex system has
48 proven to be difficult (5,6).

49 In addition to fermentation, microbes play an important role in the
50 biotransformation of dietary toxins in mammalian herbivores (4,7-10). For some
51 toxins, such as oxalate or 3,4-dihydroxy pyridine (DHP), a single species of
52 bacteria is capable of biotransforming the toxin, and this function can be
53 transferred to other mammals through microbial transplants (7,8,11, 12). For
54 other toxins, such as creosote resin, whole microbial community transplantation
55 into other mammals can increase tolerance (10).

56 Oxalate, a widely produced and ingested plant secondary compound
57 (PSC), serves as an excellent model to study diet-microbe interactions (13). It is
58 the simplest organic acid and is toxic to mammals (14-16). Oxalate can bind to
59 free calcium ions in the blood and aggregate in the kidneys to form kidney stones
60 (17). In fact, oxalate is a constituent in 80% of kidney stones in humans (17).

61 Oxalate is not metabolized by mammalian enzymes, but rather is biotransformed
62 into formate and CO₂ by gut microbes (7,18-21). While some oxalate-degrading
63 bacteria such as *Oxalobacter formigenes* biotransform oxalate for use as a
64 carbon and energy source, the growth of other oxalate-degrading bacteria such
65 as *Lactobacillus acidophilus* is inhibited by the presence of oxalate, even though
66 these bacteria will biotransform the compound when present (7,22). Additionally,
67 the by-products of microbial oxalate degradation, formate and CO₂, may be used
68 by a number of bacteria in the process of acetogenesis or methanogenesis,
69 potentially benefitting other gut bacteria not directly involved in the oxalate
70 degradation function (23). While there is no direct evidence for either
71 acetogenesis or methanogenesis, several known acetogenic taxa are prevalent
72 in the *N. albigula* gut, such as *Clostridium*, *Streptococcus*, and *Ruminococcus*
73 (24-26). These attributes make for a unique system to isolate the interactions
74 between dietary toxins and gut microbiota, along with their contribution to the
75 overall metabolism of the host.

76 The wild mammalian herbivore *Neotoma albigula* (white-throated woodrat)
77 is an ideal species to study the effects of dietary oxalate. Some populations of *N.*
78 *albigula* consume a diet composed of nearly 100% *Opuntia spp.* cactus, which
79 contains a high oxalate content (1.5% dry weight; 26). *Neotoma albigula* can
80 degrade >90% of dietary oxalate when fed artificial diets of up to 9% oxalate (dry
81 weight). This high level of oxalate degradation has been hypothesized to be the
82 result of microbial metabolism (27,28). Furthermore, *N. albigula* harbors a
83 diversity of known and potential oxalate-degrading bacteria distributed across the

84 gastrointestinal tract, including *Oxalobacter*, *Lactobacillus*, *Clostridium*, and
85 *Enterococcus* among others (26). Thus, *N. albigula* regularly consumes high
86 amounts of oxalate and harbors a diversity of bacteria that exhibit complex
87 interactions with oxalate, making it an ideal species to elucidate oxalate-
88 microbiota interactions.

89 The purpose of the current study was to identify the ecological and
90 functional interactions between dietary oxalate and the gut microbiota of *N.*
91 *albigula*. This study has two primary objectives. The first is to quantify the effect
92 of increasing oxalate consumption on oxalate degradation *in vivo*. The second is
93 to determine if the gut microbiota of *N. albigula* exhibits a community-level
94 response to oxalate consumption. Given the previously identified differential
95 responses of oxalate-degrading bacteria to the presence of oxalate, we predicted
96 that oxalate would stimulate the growth of some microbial taxa, inhibit the growth
97 of others, while having a neutral effect on the remaining community. Our data
98 supports the hypothesis that a specialized microbial network of bacteria is
99 responsible for oxalate degradation in *N. albigula*.

100 **Materials and Methods**

101 *Location, collection, and diet of animals*

102 Six individuals of the white-throated woodrat, *N. albigula*, were collected
103 with Sherman live traps from Castle Valley, Utah (38.63°N, 109.41°W), in
104 October, 2012. Woodrats were immediately transported to the University of Utah
105 Department of Biology Animal Facility and housed in individual cages (48 x 27 x
106 20 cm) under a 12:12-hr light:dark cycle, at 28°C and 20% humidity. Animals

107 were maintained in captivity and fed high-fiber rabbit chow with 0.2% oxalate
108 (Harlan Teklad formula 2031, Denver, CO, USA) for six months prior to
109 experimentation. All methods were approved by the IACUC under protocol #12-
110 12010.

111 To examine the interactions between dietary oxalate and gut microbes,
112 animals were placed in a diet trial where oxalate was gradually increased over
113 time (Table 1). The five-day time periods for the 0.05% oxalate diet were chosen
114 to ensure that any effect of oxalate on the microbiota was removed while the
115 three days for each of the oxalate diet periods were chosen based on Belenguer
116 et al. (2013) in which three days on oxalate was long enough to elicit a microbial
117 response. Metabolic cages were used to separate urine and feces and allow for
118 the quantification of food and water intake, which were given *ad libitum*. In
119 metabolic cages, *N. albigula* had access to direct coprophagy (consuming feces
120 from the anus), but not indirect coprophagy (cache feces to consume later). To
121 minimize the oxalate concentration of the rabbit chow without reducing food
122 intake, a 3:1 ratio of powdered purified rat chow (Harlan, Denver, CO, USA) to
123 powdered rabbit chow (Harlan) was used in the study. This diet contained an
124 oxalate concentration of 0.05%, which will be referred to as “no oxalate” from
125 here on (Table S1). Oxalate diets were prepared by mixing sodium oxalate
126 (Fisher Scientific, Pittsburgh, PA, USA) into the powdered chow on a dry weight
127 basis. At the end of the diet trial, all animals were returned to the no oxalate diet
128 to ensure that any effect on the microbiota was the result of oxalate and not
129 some other factor. Urine and feces were collected daily in sterile 50ml falcon

130 tubes for oxalate assays and microbial inventories. Additionally we collected data
131 on body mass, food and water intake, along with fecal and urinary output, daily.
132 Using the food intake and fecal output data, we estimated dry matter digestibility
133 (DMD) as $1 - (\text{dry fecal output} \div \text{food consumed})$. These data were evaluated
134 with repeated measures ANOVA.

135 *Oxalate Assays*

136 Oxalate in the urine was quantified by following a modified protocol
137 described by Ingale *et al.* (29). Urine samples were collected daily from each
138 animal for the assays and pooled together for each treatment period. Urine
139 samples were acidified with 3M HNO₃ to a pH of <3 to solubilize any oxalate
140 crystals. Acidified urine was centrifuged to remove precipitates and the
141 supernatant reserved. The pH of the supernatant was brought up to 7 with
142 NaOH. Approximately 0.1g of CaCl₂ was added and mixed to precipitate oxalate.
143 Samples were then centrifuged and decanted. A volume of distilled water
144 matching the total urinary volume was added to calcium oxalate precipitate.
145 Samples were then titrated as described below.

146 For fecal oxalate assays, feces for each animal were collected daily, dried
147 at 45°C overnight, and pooled by animal at the end of each treatment period.
148 Oxalate assays were conducted following a modified protocol from Justice (28).
149 Approximately 0.4g of dried feces were ground and added to 5ml 6N H₂SO₄ for
150 15 minutes to solubilize oxalate. After 15 minutes, 25ml of distilled water was
151 added and the entire solution was filtered through Grade 4 Whatman filter paper.

152 The filtrate was brought up to a pH of 7 with NaOH and 0.1g CaCl₂ was added to
153 precipitate oxalate. The samples were centrifuged and decanted. After
154 centrifugation, a volume of distilled water equal to that recovered after filtration
155 was added and the samples were titrated.

156 The urine and fecal extracts containing calcium oxalate were titrated in
157 5ml aliquots with 0.01M KMnO₄ in triplicate. Aliquots were first acidified with 1ml
158 6N H₂SO₄ and heated to 70-90°C. The KMnO₄ was then added until a pink color
159 persisted for 30sec and the volume of KMnO₄ was recorded. These volumes
160 were then compared to a standard curve. Standard curves were made by adding
161 0mM, 5mM, 10mM, 15mM, or 20mM of sodium oxalate to the urine or feces of
162 wood rats consuming 0.05% oxalate. After extraction and titration, the volume of
163 KMnO₄ required to titrate samples with no oxalate added was subtracted from all
164 samples to account for endogenous oxalate production. With these methods, we
165 are able to recover 102.69 ± 12.94% of the oxalate from urine and 97.47 ± 6.78%
166 of the oxalate from feces. Both titration curves were linear with r² values >0.9.

167 To estimate how much dietary oxalate was being degraded, we quantified
168 the difference between oxalate consumed and total oxalate excreted. This
169 estimate is conservative given that some endogenously produced oxalate is
170 excreted in the urine and feces that is not accounted for with this method.
171 However, our estimates of total oxalate excretion on the no oxalate diet indicate
172 that the endogenous contribution is typically small (<10% of oxalate consumed
173 on a 0.5% oxalate diet). Furthermore, given that endogenous oxalate production
174 is determined by the consumption of certain dietary precursors, it should not

175 change under the diet regime used in this study and is unlikely to impact the
176 conclusions drawn (15).

177 *Microbial Inventories*

178 We collected fresh feces for microbial inventories on the last day of each
179 diet treatment, which were frozen at -80°C until DNA extraction. DNA was
180 extracted from 180-220g of feces using the QIAamp DNA Stool Mini Kit (Qiagen,
181 Germantown, MD, USA). DNA extractions were also performed on oxalate, food,
182 and reagents of the extraction kit to identify potential sources of contamination.
183 Microbial inventories from a total of 36 fecal samples were generated by
184 amplifying the V4 region of the 16S rRNA gene with the primers 515F and 806R
185 (31). Primers contained a 12 base barcode sequence, which allowed for
186 multiplexing of samples within a single-lane sequencing run on an Illumina MiSeq
187 with paired end sequencing of 150 base pairs each, as previously described (31).

188 Sequences were analyzed using QIIME (32). Standard quality control was
189 conducted and sequences were demultiplexed using default parameters in
190 QIIME. A *de novo* picking strategy was used to classify operational taxonomic
191 units (OTUs) with UCLUST (33) with a minimum sequence identity of 97%. This
192 strategy resulted in an OTU table and phylogenetic tree, which were used in
193 downstream analyses. Sequences identified as chloroplasts, mitochondria, or
194 that had fewer than 10 representations across the dataset were removed.
195 Additionally, samples of microbial communities with fewer than 3000 sequence
196 reads total were removed from further data analysis. For comparative analyses,

197 samples were rarified to an equal sampling depth of 27378, which was the
198 highest number that included all samples remaining after quality control.

199 We calculated the α -diversity metrics species richness (Margalef's
200 richness index), evenness (equitability), and Shannon-Index. Community
201 membership and structure were determined using unweighted and weighted
202 UniFrac analyses respectively to compare microbial community similarity across
203 individuals and diet treatments. Unweighted UniFrac analysis compares
204 community membership, whereas the weighted analysis also takes into
205 consideration relative abundance (34). Comparisons were made with an analysis
206 of similarity (ANOSIM) after 999 permutations. Additionally, a repeated
207 measures Pearson correlation analysis between the relative abundance of an
208 OTU and oxalate consumption was conducted for all samples and OTUs. The
209 open source software QIIME was used for diversity, ANOSIM, and correlation
210 metrics with a False Discovery Rate (FDR) correction for the Pearson correlation.
211 Significance was set at a P-value <0.05 for all analyses.

212 **Results**

213 *Oxalate Degradation*

214 Body mass, food intake, DMD, water intake, and urine output, did not differ
215 significantly among treatments (Table 2). Oxalate intake increased significantly
216 with increasing dietary oxalate concentration ($P < 0.001$), and the amount of
217 oxalate degraded correlated significantly with oxalate consumption (Figure 1).
218 When excretion of endogenous oxalate is taken into consideration (i.e., by

219 subtracting the amount excreted on the no oxalate diet), oxalate degradation
220 exceeded 90% of that consumed regardless of concentration in the diet.
221 Furthermore, 94-99% of the excreted dietary oxalate was found in the feces,
222 indicating that little oxalate was absorbed into the blood.

223 *Response of Gut Microbiota*

224 High-throughput sequencing yielded a total of 2,208,347 high-quality
225 sequences of 150 overlapping base pairs. The dataset from one animal was
226 removed because two of the microbial inventories contained <3000 sequence
227 reads. Furthermore, a total of 38,723 OTUs were removed from dataset, having
228 fewer than 10 sequence reads total. The remaining inventories contained an
229 average of $69,010 \pm 5,353$ sequences per sample. Rarefaction analysis
230 concluded that the diversity at 27,378 is a good estimate of the true diversity
231 (Figure S1). With a cut-off of 27,378, and additional 15 OTUs were removed
232 from the dataset. When DNA was extracted from oxalate or food, and used as
233 template for PCR using universal 16S rRNA primers, no amplification products
234 were detected following gel electrophoresis. Similarly, the DNA extraction
235 reagents used in the study yielded no PCR amplification of 16S rRNA, indicating
236 that there was no detectable contamination. Across all fecal samples, sequences
237 were assigned to 6232 OTUs. Of these OTUs, 97.6% were assigned to 14
238 bacterial phyla with 25.3% assigned to 88 genera. The fecal microbiota showed
239 a composition typical of woodrats and other mammals that was dominated by
240 *Bacteroidetes*, particularly the family S24-7 that comprised between 49.8-67.2%
241 of the microbiota (26). There were no significant differences in community

242 membership or community structure across treatments, based on ANOSIM
243 analysis ($P=0.496$ and 0.691 respectively; Figure 2). Species richness and
244 Shannon Index increased significantly with dietary oxalate concentration;
245 however, evenness did not differ significantly (Figure 3). Species richness
246 correlated significantly with oxalate consumption (Figure 4). However, a
247 repeated measures ANOVA followed by a post-hoc Tukey's analysis revealed
248 that only the species richness on a 3% oxalate diet was significantly different
249 than on the no oxalate diet (Figure 3A). This shift in α -diversity prompted us to
250 further investigate the microbial involvement in oxalate biotransformation.

251 Of the 6232 identified OTUs, a total of 116 OTUs exhibited a significant
252 positive correlation ($P<0.05$ after a False Discovery Rate correction) with oxalate
253 consumption while one OTU exhibited a negative correlation (Table 3). Those
254 OTUs exhibiting a positive correlation included known oxalate-degrading
255 bacteria: *Oxalobacter*, another *Oxalobacteraceae sp.*, *Clostridiales*, and
256 *Lachnospiraceae* among others. The taxonomic clade with the greatest number
257 of OTUs that exhibited a positive correlation was the S24-7 family.

258 A subset of identified OTUs were shared across all animals and
259 treatments. A total of 103 OTUs were present in all six animals on the no oxalate
260 diet and 282 OTUs were shared on the 3% oxalate diet, including all of those
261 present in all animals on the no oxalate diet (Table S2).

262 **Discussion**

263 The current study sought to address two important gaps in gut microbiota
264 research. First, there is a need to understand the factors that contribute to
265 changes in the form and function of the mammalian gut microbiota, both to aid in
266 the development of personalized therapies and to advance ecological theories
267 (5,6). However, studying these factors is confounded by the complexity inherent
268 within the gut microbiota with its immense and variable diversity, and
269 considerable microbe-microbe and microbe-host interactions (2,6,35). Second,
270 there is a need to understand how oxalate affects the mammalian gut microbiota
271 as a whole. Previous research has focused on the role of individual taxa in
272 oxalate degradation (7,20,36,37,38). However, several oxalate-degrading taxa
273 have now been identified from the mammalian gut and other taxa may be
274 affected by oxalate in obscure ways (20,26,39,40). To address the gaps, we
275 combined controlled laboratory diet trials, physiological assays, and microbial
276 ecology to examine the taxonomic and functional response of the whole gut
277 microbiota in a mammalian herbivore, *N. albigula*, which naturally consumes high
278 amounts of oxalate in its diet, a simple compound that is metabolized exclusively
279 by the gut microbiota (18,26).

280 The microbiota of *N. albigula* is exceptional in its capacity to degrade
281 oxalate. The animals exhibited no adverse effects associated with oxalate intake
282 (Table 1) and the microbiota was capable of degrading >90% of dietary oxalate
283 regardless of the amount of oxalate consumed, showing a strong microbial
284 response to oxalate consumption. Studies conducted on other mammals indicate
285 that the level of dietary oxalate degradation in *N. albigula* is unique (27,28). The

286 Norway rat, *Rattus norvegicus*, becomes hyperoxaluric on a 1.5% oxalate diet
287 (42, unpublished data), whereas another study demonstrated that *N. albigula* can
288 tolerate 9% oxalate with no detrimental effect (27). One potential morphological
289 characteristic that may facilitate oxalate degradation in *N. albigula* is the
290 presence of a foregut that houses a microbiota with a high potential for oxalate
291 degradation (10,26). In metabolic cages, *N. albigula* have access to direct
292 coprophagy (consuming feces from the anus), which may help to inoculate the
293 foregut with oxalate-degrading bacteria. Given the results of the current and
294 previous studies, the gut microbiota of *N. albigula* appears to have a
295 considerable capacity for oxalate degradation, indicative of a rapid microbial
296 response to oxalate consumption.

297 Our work shows that dietary oxalate affects both the microbial community
298 diversity as a whole in *N. albigula* as well as the relative abundance of specific
299 OTUs. The correlation between oxalate consumption and species richness
300 (Figure 3A) suggests that OTUs that were present below detectable limits on a
301 no oxalate diet increased in relative abundance with higher oxalate consumption
302 to detectable levels. Such a correlation between the consumption of (natural)
303 dietary toxins and gut microbiota diversity has been observed in other woodrat
304 studies and is likely indicative of a dynamic, community-wide adaptation to
305 dietary change (43). Although there was a strong individual signature to the gut
306 microbiota in the current study, some OTUs were both broadly distributed among
307 animals in general and exhibited a significant correlation with oxalate
308 consumption (Tables 3,S2). The subset of microbes that increased with oxalate

309 consumption may represent a core community of microbes essential for the
310 function of oxalate degradation, or an “oxalate microbiome”.

311 A core gut microbiota has previously been associated with diverse
312 mammalian host phenotypes (44-46). In the current study, we have identified a
313 core set of bacteria that are commonly distributed across individuals and are
314 responsive to oxalate, suggesting that this microbial network may be important in
315 reducing oxalate absorption in *N. albigula*. Some of the bacteria in this group,
316 such as *Oxalobacter*, may engage in oxalate degradation directly. Others such
317 as *Oscillospora* and *Clostridiales* may benefit indirectly from oxalate degradation
318 possibly via acetogenesis and facilitate the continued presence of those bacteria
319 that degrade oxalate.

320 Strategies to utilize known oxalate-degrading bacteria as probiotic
321 therapies to reduce urinary oxalate excretion in humans and rat models typically
322 only result in an ephemeral reduction of urinary oxalate and a transient
323 colonization by the probiotic bacteria (11,37,42,47,48). This is in contrast to
324 mammals that are natural hosts to oxalate-degrading bacteria, such as the
325 animals in the current study, that maintain those populations and their associated
326 functions across generations and respond to increasing dietary oxalate even after
327 long periods of time without oxalate in the diet (38,49,50). The transient
328 colonization of the oxalate-degrading bacteria following probiotic treatment
329 suggests that these transplanted bacteria are unable to integrate successfully
330 into a foreign community, implying that there are underlying mechanisms of
331 support for these bacteria in their natural hosts.

332 The S24-7 family appears to play a critical role both in the oxalate
333 microbiome specifically and in the gut microbiota of *N. albigula* generally. This
334 family comprised 43% of the OTUs that exhibited a significant correlation with
335 oxalate consumption and consistently makes up >50% of the entire gut
336 microbiota in *N. albigula* (10, this study). This family is commonly found in rats,
337 mice, goats, and humans, and has also been correlated with a high fat diet,
338 immunoglobulin A, tapeworms, etc. Thus, the S24-7 family may generally be
339 sensitive to dietary shifts (51-55). Given the widespread distribution of this family
340 and correlation with a number of dietary components, S24-7 represents a
341 significant gap in our understanding of the gut microbiota form and function.

342 Oxalate is a simple molecular compound with characteristics that make it
343 amenable to elucidating specific diet-microbiota interactions within the
344 mammalian gut. In the current study, we were able to predict identities for a sub-
345 community of microbes that exhibits a strong, rapid response to oxalate
346 ingestion. Our results suggest that a distinct oxalate metabolizing
347 microbiome exists that increases in abundance when oxalate is consumed.
348 Furthermore, we have shown that the methods utilized here are effective at
349 identifying sub-communities within the mammalian gut microbiota that engage in
350 a particular function of interest that may be useful to manipulate in a therapeutic
351 context.

352 **Funding Information**

353 NSF (grant DEB-1342615 to M. Denise Dearing and Colin Dale)

354 NIH (grant 1F32DK102277-01A1 to Aaron W. Miller)

355 Funding agencies had no role in study design, data collection and interpretation,
356 or the decision to submit the work for publication.

357 **Acknowledgements**

358 The authors declare that we have no conflicts of interest. We thank Kevin Kohl
359 for help collecting animals, Jesse Nelson for help with diet trials, and Ky-Phuong
360 Luong for comments on the manuscript. We thank Bob Weiss for feedback on
361 the experiment.

362 **References**

- 363 1. **Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS,**
364 **Schlegel ML, Tucker TA, Schrenzel MD, Knight R.** 2008. Evolution of
365 mammals and their gut microbes. *Science* **320**(5883):1647-1651.
- 366 2. **Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T,**
367 **Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang**
368 **B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen**
369 **T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-**
370 **Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S,**
371 **Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K,**
372 **Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P,**
373 **Ehrlich SD, Wang J.** 2010. A human gut microbial gene catalogue established
374 by metagenomic sequencing. *Nature* **464**(7285):59-65.

- 375 3. **Muegge BD, Kuczynski J, Knights D, Clemente JC, Gonzalez A, Fontana**
376 **L, Henrissat B, Knight R, Gordon JI.** 2011 Diet drives convergence in gut
377 microbiome functions across mammalian phylogeny and within humans. *Science*
378 **332**(6032):970-974.
- 379 4. **Karasov WH, Carey HV.** 2009. Metabolic teamwork between gut microbes
380 and host. *Micro.* **4**(7):323-328.
- 381 5. **Fierer N, Lauber CL, Ramirez KS, Zaneveld J, Bradford MA, Knight R.**
382 2012. Comparative metagenomic, phylogenetic and physiological analyses of soil
383 microbial communities across nitrogen gradients. *ISME J.* **6**(5):1007-1017.
- 384 6. **Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R.** (2012)
385 Diversity, stability and resilience of the human gut microbiota. *Nature*
386 **489**(7415):220-230.
- 387 7. **Allison MJ, Dawson KA, Mayberry WR, Foss JG.** 1985. *Oxalobacter*
388 *formigenes* gen. nov., sp. nov.: Oxalate-degrading anaerobes that inhabit the
389 gastrointestinal tract. *Arch. Microbiol.* **141**(1):1-7.
- 390 8. **Jones R, Megarrity, R.** 1986. Successful transfer of DHP-degrading bacteria
391 from hawaiian goats to australian ruminants to overcome the toxicity of
392 *Leucaena*. *Aust. Vet. J.* **63**(8):259-262.
- 393 9. **Sundset MA, Barboza PS, Green TK, Folkow LP, Blix AS, Mathiesen SD.**
394 2010. Microbial degradation of usnic acid in the reindeer rumen.
395 *Naturwissenschaften* **97**(3):273-278.

- 396 10. **Kohl KD, Weiss RB, Cox J, Dale C, Dearing MD.** 2014. Gut microbes of
397 mammalian herbivores facilitate intake of plant toxins. *Ecol. Lett.* **17**(10):1238-
398 1246.
- 399 11. **Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.** 2011. Enteric
400 oxalate elimination is induced and oxalate is normalized in a mouse model of
401 primary hyperoxaluria following intestinal colonization with *Oxalobacter*. *Am. J.*
402 *Physiol. Gastrointest. Liver Physiol.* **300**(3):G461-9.
- 403 12. **Wallace JR.** 2008. Gut microbiology-broad genetic diversity, yet specific
404 metabolic niches. *Animal.* **2**:661-668.
- 405 13. **Franceschi VR, Nakata PA.** 2005. Calcium oxalate in plants: Formation and
406 function. *Ann. Rev. Plant Bio.* **56**:41-71.
- 407 14. **James LF, Butcher JE.** 1972. *Halogeton* poisoning of sheep: Effect of high
408 level oxalate intake. *J. Anim. Sci.* **35**(6):1233-1238.
- 409 15. **Conyers RA, Bais R, Rofe AM.** 1990. The relation of clinical catastrophes,
410 endogenous oxalate production, and urolithiasis. *Clin. Chem.* **36**(10):1717-1730.
- 411 16. **Massey LK, Roman-Smith H, Sutton RA.** 1993. Effect of dietary oxalate
412 and calcium on urinary oxalate and risk of formation of calcium oxalate kidney
413 stones. *J. Am. Diet. Assoc.* **93**(8):901-906.
- 414 17. **Moe OW.** 2006. Kidney stones: pathophysiology and medical management.
415 *The Lancet* **367**(9507):333-344.
- 416 18. **Hodgkinson A.** 1977. Oxalic acid in biology and medicine. New York:
417 Academic Press.

- 418 19. **Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV.** 1986. Oxalate
419 degradation by gastrointestinal bacteria from humans. *J. Nutr.* **116**(3):455-460.
- 420 20. **Hokama S, Honma Y, Toma C, Ogawa Y.** 2000. Oxalate-Degrading
421 *Enterococcus faecalis*. *Microbiol. Immunol.* **44**(4):235-240.
- 422 21. **Ren Z, Pan C, Jiang L, Wu C, Liu Y, Zhong Z, Ran L, Ren F, Chen X,**
423 **Wang Y, Zhu Y, Huang K.** 2011. Oxalate-degrading capacities of lactic acid
424 bacteria in canine feces. *Vet. Microbiol.* **152**(3):368-373.
- 425 22. **Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S,**
426 **Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C.** 2001. Reduction of
427 oxaluria after an oral course of lactic acid bacteria at high concentration. *Kidney*
428 *Int.* **60**(3):1097-1105.
- 429 23. **Drake HL** 2012. *Acetogenesis*. Springer Science and Business Media: New
430 York, NY.
- 431 24. **Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez-Garayzabal**
432 **J, Garcia P, Cai J, Hippe H, Farrow JAE.** 1994. The phylogeny of the genus
433 *Clostridium*: proposal of five new genera and eleven new species combinations.
434 *Int. J. Syst. Bacter.* **44**(4): 812-826
- 435 25. **Leclerc M, Bernalier A, Donadille G, Lelait M.** 1997. H₂/CO₂ metabolism in
436 acetogenic bacteria isolated from the human colon. *Anaerobe.* **3**(5): 307-315.
- 437 26. **Miller AW, Kohl KD, Dearing MD.** 2014. The gastrointestinal tract of the
438 white-throated woodrat (*Neotoma albigula*) harbors distinct consortia of oxalate-
439 degrading bacteria. *Appl. Environ. Microbiol.* **80**(5):1595-1601.

- 440 27. **Shirley EK, Schmidt-Nielsen K.** 1967. Oxalate metabolism in the pack rat,
441 sand rat, hamster, and white rat. *J. Nutr.* **91**:496-502.
- 442 28. **Justice KE.** 1985. Oxalate digestibility in *Neotoma albigula* and *Neotoma*
443 *mexicana*. *Oecologia* **67**(2):231-234.
- 444 29. **Ingale KG, Thakurdesai PA, Vyawahare NS.** 2012. Effect of *Hygrophila*
445 *spinosa* in ethylene glycol induced nephrolithiasis in rats. *Indian J. of Pharmacol.*
446 **44**(5):639.
- 447 30. **Caporaso JG, Lauber CL, Walters, WA, Berg-Lyons D, Lozupone CA,**
448 **Turnbaugh PJ, Fierer N, Knight R.** 2011. Global patterns of 16S rRNA diversity
449 at a depth of millions of sequences per sample. *Proc. Natl. Acad. Sci. USA*
450 **108**(1):4516-4522.
- 451 31. **Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer**
452 **N, Owens S, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G,**
453 **Knight R.** 2012. Ultra-high-throughput microbial community analysis on the
454 illumina HiSeq and MiSeq platforms. *ISME J.* **6**(8):1621-1624.
- 455 32. **Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD,**
456 **Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley**
457 **ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD,**
458 **Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J,**
459 **Yatsunenko T, Zaneveld J, Knight R.** 2010. QIIME allows analysis of high-
460 throughput community sequencing data. *Nature Meth* **7**(5):335-336.
- 461 33. **Edgar RC.** 2010. Search and clustering orders of magnitude faster than
462 BLAST. *Bioinform.* **26**(19):2460-2461.

- 463 34. **Lozupone CA, Hamady H, Knight R.** 2006. UniFrac – an online tool for
464 comparing microbial community diversity in a phylogenetic context. BMC
465 Bioinform. **7**(1):371.
- 466 35. **Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA.**
467 2012. The application of ecological theory toward an understanding of the human
468 microbiome. Science **336**(6086):1255-1262.
- 469 36. **Daniel SL, Hartman PA, Allison MJ.** 1987. Intestinal colonization of
470 laboratory rats with *Oxalobacter formigenes*. Appl. Environ. Microbiol.
471 **53**(12):2767-2770.
- 472 37. **Hoppe B, Beck B, Gatter N, Von Unruh G, Tischler A, Hesse A, Laube N,**
473 **Kaul P, Sidhu H.** 2006. *Oxalobacter formigenes*: A potential tool for the
474 treatment of primary hyperoxaluria type 1. Kidney Int. **70**(7):1305-1311.
- 475 38. **Belenguer A, Ben Bati M, Hervás G, Toral PG, Yáñez-Ruiz DR, Frutos P.**
476 2013. Impact of oxalic acid on rumen function and bacterial community in sheep.
477 Ani. **7**(6): 940-947.
- 478 39. **Murphy C, Murphy S, O'Brien F, O'Donoghue M, Boileau T, Sunvold G,**
479 **Reinhart G, Kiely B, Shanahan F, O'Mahony L.** 2009. Metabolic activity of
480 probiotics-Oxalate degradation. Vet. Microbio. **136**(1-2):100-107.
- 481 40. **Turrone S, Bendazzoli C, Dipalo SCF, Candela M, Vitali B, Gotti R, Brigidi**
482 **P.** 2010. Oxalate-degrading activity in *Bifidobacterium animalis* subsp. *lactis*:
483 Impact of acidic conditions on the transcriptional levels of the oxalyl-CoA
484 decarboxylase and formyl-CoA transferase genes. Appl. Environ. Microbio.
485 **7**(16):5609-5620.

- 486 41. **Allison MJ, Cook HM.** 1981. Oxalate degradation by microbes of the large
487 bowel of herbivores: The effect of dietary oxalate. *Science* **8**(212):675-676.
- 488 42. **Lieske JC, Tremaine WJ, De Simone C, O'Conner HM, Li X, Bergstralh E,**
489 **Goldfarb DS.** 2010. Diet, but not oral probiotics, effectively reduces urinary
490 oxalate excretion and calcium oxalate supersaturation. *Kidney Int.* **78**(11):1178-
491 1185.
- 492 43. **Kohl KD, Dearing MD.** 2012. Experience matters: Prior exposure to plant
493 toxins enhances diversity of gut microbiome in herbivores. *Eco. Lett.* **15**(9):1008-
494 1015.
- 495 44. **Sekelja M, Berget I, Naes T, Rudi K.** 2011. Unveiling an abundant core
496 microbiota in the human adult colon by a phylogroup-independent searching
497 approach. *ISME J.* **5**(3):519-531.
- 498 45. **Pédrón T, Mulet C, Dauga C, Frangeul L, Chervaux C, Grompone G,**
499 **Sansonetti PJ.** 2012. A crypt-specific core microbiota resides in the mouse
500 colon. *M. Bio.* **3**(3):e00116-12.
- 501 46. **Elli M, Colombo O, Tagliabue A.** 2010. A common core gut microbiota
502 between obese individuals and their lean relatives? Evaluation of the
503 predisposition to obesity on the basis of the fecal microflora profile. *Med.*
504 *Hypothes.* **75**(4): 350-352.
- 505 47. **Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB.** 2001. Rapid reversal of
506 hyperoxaluria in a rat model after probiotic administration of *Oxalobacter*
507 *formigenes*. *J. Urol.* **166**(4):1487-1491.

- 508 48. **Knight J, Deora R, Assimos DG, Holmes RP.** 2013. The genetic
509 composition of *Oxalobacter formigenes* and its relationship to colonization and
510 calcium oxalate stone disease. *Urolithiasis* **41**(3):187-196.
- 511 49. **Allison MJ, Littledike E, James L.** 1977. Changes in ruminal oxalate
512 degradation rates associated with adaptation to oxalate ingestion. *J. Anim. Sci.*
513 **45**(5):1173-1179.
- 514 50. **Palgi N, Ronen Z, Pinshow B.** 2008. Oxalate balance in fat sand rats
515 feeding on high and low calcium diets. *J. Comp. Phys. B* **178**:617-622.
- 516 51. **Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, Waget A, Klopp**
517 **P, Iacovoni J, Klopp C, Mariette J, Bouchez O, Lluch J, Ouarné F, Monsan**
518 **P, Valet P, Roques C, Amar J, Bouloumié A, Théodorou V, Burcelin R.** 2012.
519 Metabolic adaptation to a high-fat diet is associated with a change in the gut
520 microbiota. *Gut* **61**(4):543-553.
- 521 52. **Kato T, Fukuda S, Fujiwara A, Suda W, Hattori M, Kikuchi J, Ohno H.**
522 2014. Multiple omics uncovers host-gut microbial mutualism during prebiotic
523 fructooligosaccharide supplementation. *DNA Res.* **21**(5):469-480.
- 524 53. **Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S,**
525 **Dougherty J, Moulton L, Glawe A, Wang Y, Leone V, Antonopoulos DA,**
526 **Smith D, Chang EB, Ciancio MJ.** 2014. Exercise prevents weight gain and
527 alters the gut microbiota in a mouse model of high-fat diet induced obesity.
528 *PLOS One* **9**(3): e92193.
- 529 54. **Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L,**
530 **Degnan PH, Hu J, Peter I, Zhang W, Ruggiero E, Cho JH, Goodman AL,**

531 **Flavell RA.** 2014. Immunoglobulin A coating identifies colitogenic bacteria in
532 inflammatory bowel disease. *Cell* **158**(5):1000-1010.
533 **55. Kreisinger J, Bastien G, Hauffe HC, Marchesi J, Perkins SE.** 2015.
534 Interactions between multiple helminths and the gut microbiota in wild rodents.
535 *Phil. Trans. R. Soc. B.* **370**(1675):20140295.
536

537 Figure legends

538 Figure 1. The amount of oxalate consumed correlated with the amount of oxalate
539 degraded (estimated by the differential between oxalate consumed and the total
540 oxalate excreted in the urine and feces). Data was analyzed with a repeated
541 measures Pearson correlation ($r = 0.99845$, $P < 0.001$). Oxalate consumed also
542 increased significantly with increasing oxalate consumption as determined by a
543 repeated measures ANOVA with a posthoc, Holm's corrected Tukey's analysis
544 (statistical groups shown by bolded letters).

545 Figure 2. The relative abundance of the major phyla present within the gut at
546 different dietary oxalate concentrations over time. The "other" category contains
547 several phyla with minor contributions to the microbiota. Columns are ordered
548 relative to the time series of the experiment. Neither community membership nor
549 structure changed with oxalate treatment ($P = 0.496$ and 0.691 respectively).

550 Figure 3. Alpha-diversity metrics between different dietary oxalate treatments.
551 Species richness was determined with Margalef's richness index; species
552 evenness was determined by their equitability; the Shannon Index is a
553 combination of species richness and evenness. The statistical analyses were
554 repeated measures ANOVA followed by a Holm's-corrected paired t-test. Similar
555 letters indicate statistically similar treatment groups. Order of columns reflects the
556 time series of the experiment.

557 3A) Species richness: Repeated measures ANOVA $F(5,30)=2.67$, $P=0.044$.

558 3B) Species evenness: Repeated measures ANOVA $F(5,30)= 1.1126$, $P=0.38$.

559 3C) The Shannon Index: Repeated measures ANOVA $F(5,30)=2.9928$, $P=0.031$.

560 Figure 4. Species richness was correlated with oxalate consumption (repeated
561 measures Pearson correlation with $P=0.001$ and $r=0.529$). Symbols represent
562 mean oxalate consumption and species richness for each treatment.




Figure 1. The amount of oxalate consumed correlated with the amount of oxalate degraded (estimated by the differential between oxalate consumed and the total oxalate excreted in the urine and feces). Data was analyzed with a repeated measures Pearson correlation ($r = 0.99845$, $P < 0.001$). Oxalate consumed also increased significantly with increasing oxalate consumption as determined by a repeated measures ANOVA with a posthoc, Holm's corrected Tukey's analysis (statistical groups shown by bolded letters).




Figure 2. The relative abundance of the major phyla present within the gut at different dietary oxalate concentrations over time. The “other” category contains several phyla with minor contributions to the microbiota. Columns are ordered relative to the time series of the experiment. Neither community membership nor structure changed with oxalate treatment (Anosim; $P = 0.496$ and 0.691 respectively).






Figure 3. Alpha-diversity metrics between different dietary oxalate treatments. Species richness was determined with Margalef's richness index; species evenness was determined by their equitability; the Shannon Index is a combination of species richness and evenness. The statistical analyses were repeated measures ANOVA followed by a Holm's-corrected paired t-test. Similar letters indicate statistically similar treatment groups. Order of columns reflects the time series of the experiment.

3A) Species richness: Repeated measures ANOVA $F(5,30)=2.67$, $P=0.044$.



3B) Species evenness: Repeated measures ANOVA $F(5,30)= 1.1126$, $P=0.38$.



3C) The Shannon Index: Repeated measures ANOVA $F(5,30)=2.9928$, $P=0.031$.




Figure 4. Species richness was correlated with oxalate consumption (repeated measures Pearson correlation with $P=0.001$ and $r=0.529$). Symbols represent mean oxalate consumption and species richness for each treatment.

Diet	Duration
No oxalate	5 days
0.5% oxalate	3 days
1% oxalate	3 days
1.5% oxalate	3 days
3% oxalate	3 days
No oxalate	5 days

Table 1. The design of the diet trial. Oxalate percentage was determined by mass.

Metric	Mean (g) +/- SE	F-value	P-value
Body Mass	171.08 +/- 12.83	0.06	1.00
Food Intake	18.71 +/- 0.06	1.66	0.18
Fecal Output	1.907 +/- 0.088	3.16	0.27
DMD	0.758 +/- 0.012	0.88	0.49
Water Intake	12.71 +/- 2.25	0.74	0.57
Urine Output	5.88 +/- 0.96	0.39	0.82

Table 2. Metrics associated with woodrats that were not significantly affected by oxalate. Means were compared over the course of the experiment with a repeated measures ANOVA (df = 5,30). Shown are the global mean for each metric.

Lowest Assigned Taxonomy	Taxonomic Level	# of OTUs	Relative Abundance 0% Oxalate	Relative Abundance 3% Oxalate	r	P
<i>Oscillospira</i>	genus	4	$1 \cdot 10^{-4}$	$5.8 \cdot 10^{-3}$	0.54 ± 0.037	0.009-0.037
<i>Oxalobacter</i>	genus	1	$6.39 \cdot 10^{-5}$	$5.24 \cdot 10^{-4}$	0.54	0.031
<i>Clostridiales</i>	order	16	$9.13 \cdot 10^{-6}$	$1.03 \cdot 10^{-3}$	0.52 ± 0.015	0.009-0.04
<i>Ruminococcus</i>	genus	5	0	$3.29 \cdot 10^{-4}$	0.52 ± 0.015	0.031-0.038
<i>Allobaculum</i>	genus	3	0	$3.29 \cdot 10^{-4}$	0.51 ± 0.017	0.031-0.034
<i>S24-7</i>	family	50	$1.01 \cdot 10^{-3}$	$1.27 \cdot 10^{-2}$	0.51 ± 0.007	0.009-0.041
<i>Lactobacillus</i>	genus	1	0	$2.44 \cdot 10^{-5}$	0.51	0.031
<i>Oxalobacteraceae</i>	family	1	$5.48 \cdot 10^{-5}$	$6.09 \cdot 10^{-4}$	0.51	0.032
<i>RF39</i>	order	1	0	$1.22 \cdot 10^{-5}$	0.51	0.031
<i>Bifidobacterium</i>	genus	3	$9.13 \cdot 10^{-6}$	$1.83 \cdot 10^{-3}$	0.50 ± 0.022	0.031-0.04
<i>Unassigned</i>	N/A	19	$4.57 \cdot 10^{-5}$	$8.52 \cdot 10^{-4}$	0.49 ± 0.007	0.031-0.044
<i>Ruminococcaceae</i>	family	3	$2.74 \cdot 10^{-5}$	$3.17 \cdot 10^{-4}$	0.48 ± 0.02	0.031-0.044
<i>Lachnospiraceae</i>	family	3	$3.65 \cdot 10^{-5}$	$2.19 \cdot 10^{-4}$	0.48 ± 0.017	0.031-0.043
<i>Rikenellaceae</i>	family	4	$9.13 \cdot 10^{-6}$	$1.87 \cdot 10^{-3}$	0.48 ± 0.004	0.034-0.037
<i>Coprococcus</i>	genus	1	0	$2.44 \cdot 10^{-5}$	0.48	0.034
<i>Proteus</i>	genus	1	0	$2.44 \cdot 10^{-5}$	0.46	0.04
<i>Salinibacterium</i>	genus	1	$2.74 \cdot 10^{-5}$	0	-0.46	0.039

Table 3. Microbial OTUs (out of 6232) whose relative abundances were positively correlated with oxalate intake (Pearson Correlation regression analysis, with a False Discovery Rate (FDR) correction for multiple comparisons). For taxa with multiple OTUs that were correlated with oxalate consumption, the average r-

values and range of P-values are given and the relative abundance refers to the group of OTUs as a whole.